TY-51469
目录号 : GC32004
TY-51469是糜蛋白酶(chymase)抑制剂，在类人猿和人糜蛋白酶的IC50值分别为0.4和7.0nM。
Cas No.:603987-59-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
TY-51469 is a chymase inhibitor with IC50s for simian and human chymases of 0.4 and 7.0 nM, respectively.
TY-51469 shows 100% stability in rat plasma at 40°C for as long as 1 hour[1]. TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice[2].
[1]. Takato H, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Expert Opinion on Therapeutic Targets Volume 15, 2011 - Issue 4.
Animal experiment: | Rats[1] The 2-week intravenous repeated-dose toxicity study of TY-51469 was conducted in male Sprague-Dawley rats at daily doses of 0 (control), 20, and 60 mg/kg[1].Mice[1]the chymase inhibitor TY-51469 was administered daily at a dose of 0.1 or 1.0 mg/kg/day for 21 days using an osmotic pump to male 8-week-old ICR mice. The osmotic pump released the drug solution continuously at a rate of 0.3 µL/h for 21 days[2]. |
References: [1]. Takato H, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Expert Opinion on Therapeutic Targets Volume 15, 2011 - Issue 4. | |
| Cas No. | 603987-59-3 | SDF | |
| Canonical SMILES | O=C(C1=CSC(C2=CC=C(NS(=O)(C3=C(C)C4=CC(F)=CC=C4S3)=O)C(S(=O)(C)=O)=C2)=N1)O | ||
| 分子式 | C20H15FN2O6S4 | 分子量 | 526.6 |
| 溶解度 | DMSO : 33.33 mg/mL (63.29 mM; Need ultrasonic) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.899 mL | 9.4949 mL | 18.9897 mL |
| 5 mM | 0.3798 mL | 1.899 mL | 3.7979 mL |
| 10 mM | 0.1899 mL | 0.9495 mL | 1.899 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet